Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Breast lumps secondary prevention

Introduction

Overview

Overview

Secondary prevention of breast lumps consists of modifiable risk factors and preventive factors to decrease the rates of breast cancer. The protective factors include controlling alcohol consumption, weight control, physical activity, healthy diet, breast feeding, prophylactic bilateral oophorectomy for BRCA1 and BRCA2 carriers, hormonal replacement therapy avoidance, and use of tamoxifen for high risk women aged > 35 years. In order to reduce breast cancer recurrence, surveillance and follow-up by either physical examination and mammography are required.

Secondary prevention

Secondary prevention

Benign breast lesions require great attention regarding its influence on patient’s quality of life, high prevalence, and the potential of becoming malignant.[1]

  • Prevention is considered as the primary method to decrease incidence of new cases of breast cancer.[2]
  • Prevention of breast disease may be associated with establishing modifiable risk factors.
  • Modifiable risk factor in pre-menopausal women include:
    • Alcohol intake:
      • No alcohol intake for youth aged 12-17 years may lead to 20-30% possible risk reduction and takes 10-20 years for the benefit of decreasing the risk.[3][4]
      • ≀1 serving/day alcohol intake for young adults 18-24 years may lead to 20-30% possible risk reduction and take 10-20 years for the benefit of decreasing the risk.[4]
      • ≀1 serving/day alcohol intake for adults β‰₯18 years may lead to 35% possible risk reduction and take 10-20 years for the benefit of decreasing the risk.[5][6]
    • Weight control:
      • Avoid weight gain in all women may lead to 50% risk reduction after menopause and take 10-30 years for the benefit of decreasing the risk.[7]
    • Physical activity:
      • β‰₯ 30 min/day, for inactive women may lead to 20% risk reduction and take 10-30 years for the benefit of decreasing the risk.[8]
    • Healthy diet:
      • Such as fruit, vegetables, and whole grains may lead to 20-50% risk reduction and take 5-20 years for the benefit of decreasing the risk.[9][10]
    • Breast feeding:
      • At least 1 year of breast feeding after delivery of a pregnant women may lead to 18% risk reduction and take 5 years for the benefit of decreasing the risk.[11]
    • Prophylactic bilateral oophorectomy:
      • For carriers of BRCA1 and BRCA2, oophorectomy may lead to 50% risk reduction and take β‰₯ 2 years for the benefit of decreasing the risk[12]
    • Tamoxifen:
      • Use of tamoxifen in high risk women aged β‰₯35 years may lead to 50% risk reduction and take 2 years for the benefit of decreasing the risk.[13]
  • Modifiable risk factor in post-menopausal women include:
    • Alcohol intake:
      • ≀1 serving/d may lead to 35% risk reduction and take 5-10 years for the benefit of decreasing the risk.[6]
    • Weight control:
      • Weight loss for overweight and obese women > 145 lbs may lead to 50% risk reduction and take 2-5 years for the benefit of decreasing the risk.[7]
    • Physical activity:
      • β‰₯30 min/day for women (who have no contraindication to physical activity) may lead to 20% risk reduction and take 10-20 years for the benefit of decreasing the risk.[8]
    • Avoid estrogen and progestin postmenopausal hormone therapy[14]
      • May lead to 10% risk reduction for current users and take 1 year for the benefit of decreasing the risk.
      • May lead to 50% risk reduction for current users and take 2 years for the benefit of decreasing the risk.
    • Usage of tamoxifen and raloxifen:
      • For high risk women with greater than or equal risk for average woman aged 60 years, use of tamoxifen and raloxifen may lead to 50% risk reduction and take 2 years for the benefit of decreasing the risk.[15]

Surveillance and Follow-up

References

References

  1. ↑ Goehring C, Morabia A (1997). “Epidemiology of benign breast disease, with special attention to histologic types”. Epidemiol Rev. 19 (2): 310–27. PMIDΒ 9494790.
  2. ↑ Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW (2013). “Cancer genome landscapes”. Science. 339 (6127): 1546–58. doi:10.1126/science.1235122. PMCΒ 3749880. PMIDΒ 23539594.
  3. ↑ Liu Y, Tamimi RM, Berkey CS, Willett WC, Collins LC, Schnitt SJ; et al. (2012). “Intakes of alcohol and folate during adolescence and risk of proliferative benign breast disease”. Pediatrics. 129 (5): e1192–8. doi:10.1542/peds.2011-2601. PMCΒ 3866773. PMIDΒ 22492774.
  4. ↑ 4.0 4.1 Liu Y, Colditz GA, Rosner B, Berkey CS, Collins LC, Schnitt SJ; et al. (2013). “Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk”. J Natl Cancer Inst. 105 (20): 1571–8. doi:10.1093/jnci/djt213. PMCΒ 3797023. PMIDΒ 23985142.
  5. ↑ Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC (2011). “Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk”. JAMA. 306 (17): 1884–90. doi:10.1001/jama.2011.1590. PMCΒ 3292347. PMIDΒ 22045766.
  6. ↑ 6.0 6.1 Smith-Warner SA, Spiegelman D, Yaun SS, van den Brandt PA, Folsom AR, Goldbohm RA; et al. (1998). “Alcohol and breast cancer in women: a pooled analysis of cohort studies”. JAMA. 279 (7): 535–40. PMIDΒ 9480365.
  7. ↑ 7.0 7.1 Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2006). “Adult weight change and risk of postmenopausal breast cancer”. JAMA. 296 (2): 193–201. doi:10.1001/jama.296.2.193. PMIDΒ 16835425.
  8. ↑ 8.0 8.1 Bernstein L, Patel AV, Ursin G, Sullivan-Halley J, Press MF, Deapen D; et al. (2005). “Lifetime recreational exercise activity and breast cancer risk among black women and white women”. J Natl Cancer Inst. 97 (22): 1671–9. doi:10.1093/jnci/dji374. PMIDΒ 16288120.
  9. ↑ Jung S, Spiegelman D, Baglietto L, Bernstein L, Boggs DA, van den Brandt PA; et al. (2013). “Fruit and vegetable intake and risk of breast cancer by hormone receptor status”. J Natl Cancer Inst. 105 (3): 219–36. doi:10.1093/jnci/djs635. PMCΒ 3593764. PMIDΒ 23349252.
  10. ↑ Korde LA, Wu AH, Fears T, Nomura AM, West DW, Kolonel LN; et al. (2009). “Childhood soy intake and breast cancer risk in Asian American women”. Cancer Epidemiol Biomarkers Prev. 18 (4): 1050–9. doi:10.1158/1055-9965.EPI-08-0405. PMIDΒ 19318430.
  11. ↑ Collaborative Group on Hormonal Factors in Breast Cancer (2002). “Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease”. Lancet. 360 (9328): 187–95. doi:10.1016/S0140-6736(02)09454-0. PMIDΒ 12133652.
  12. ↑ Rebbeck TR, Kauff ND, Domchek SM (2009). “Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers”. J Natl Cancer Inst. 101 (2): 80–7. doi:10.1093/jnci/djn442. PMCΒ 2639318. PMIDΒ 19141781.
  13. ↑ Bernard Fisher, Joseph P. Costantino, D. Lawrence Wickerham, Carol K. Redmond, Maureen Kavanah, Walter M. Cronin, Victor Vogel, AndrΓ© Robidoux, Nikolay Dimitrov, James Atkins, Mary Daly, Samuel Wieand, Elizabeth Tan-Chiu, Leslie Ford, Norman Wolmark, other National Surgical Adjuvant Breast, Bowel Project Investigators; Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, JNCI: Journal of the National Cancer Institute, Volume 90, Issue 18, 16 September 1998, Pages 1371–1388, https://doi.org/10.1093/jnci/90.18.1371
  14. ↑ Colditz GA, Bohlke K (2014). “Priorities for the primary prevention of breast cancer”. CA Cancer J Clin. 64 (3): 186–94. doi:10.3322/caac.21225. PMIDΒ 24647877.
  15. ↑ Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J; et al. (2013). “Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline”. J Clin Oncol. 31 (23): 2942–62. doi:10.1200/JCO.2013.49.3122. PMIDΒ 23835710.
  16. ↑ de Bock GH, Bonnema J, van der Hage J, Kievit J, van de Velde CJ (2004). “Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review”. J Clin Oncol. 22 (19): 4010–8. doi:10.1200/JCO.2004.06.080. PMIDΒ 15459225.

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]